StreetInsider.com News Articles

Form 10-Q FIREFLY NEUROSCIENCE, For: Jun 30

Tue, 11 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260811/26900375.html

Form 10-Q FIREFLY NEUROSCIENCE, For: Jun 30

Tue, 11 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260811/26900375.html

Form 8-K FIREFLY NEUROSCIENCE, For: Aug 05

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891550.html

Form 8-K FIREFLY NEUROSCIENCE, For: Aug 05

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891550.html

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Wed, 05 Aug 2026 07:45:00 -0400

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future value

By combining qEEG and ERP, Evoke™ provides a more complete view of brain activity, designed to help clinicians identify patterns, differentiate

Firefly Neuroscience partners with Next Health on cognitive health platform

Tue, 28 Jul 2026 07:50:25 -0400

Firefly Neuroscience, Inc. (NASDAQ: AIFF) and Next Health announced a partnership to launch a cognitive health platform that combines Firefly's FDA-cleared EEG/ERP brain biomarker technology with personalized peptide protocols, according to a press release issued July 28, 2026.

The platform is intended to give physicians objective measures of brain function to help guide and monitor cognitive therapies. The companies plan to develop standardized clinical protocols integrating Firefly's AI-powered Evoke System with provider-guided peptide therapies across Next Health's network of longevity clinics.

The announcement follows a recommendation by an FDA Advisory Committee to add six therapeutic peptides — including Epitalon and Semax —

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

KENMORE, N.Y. and LOS ANGELES, July 28, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, and Next Health, a global leader in health optimization and

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Tue, 28 Jul 2026 07:50:00 -0400

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –

Form DEF 14A FIREFLY NEUROSCIENCE, For: Aug 05

Thu, 09 Jul 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260709/26750006.html

Form DEF 14A FIREFLY NEUROSCIENCE, For: Aug 05

Thu, 09 Jul 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260709/26750006.html

Form 424B3 FIREFLY NEUROSCIENCE,

Thu, 02 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260702/26728459.html

Form 424B3 FIREFLY NEUROSCIENCE,

Thu, 02 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260702/26728459.html

Form EFFECT FIREFLY NEUROSCIENCE,

Wed, 01 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260701/26716306.html

Form EFFECT FIREFLY NEUROSCIENCE,

Wed, 01 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260701/26716306.html

Form PRE 14A FIREFLY NEUROSCIENCE, For: Aug 05

Mon, 29 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707114.html

Form PRE 14A FIREFLY NEUROSCIENCE, For: Aug 05

Mon, 29 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707114.html

Form 8-K FIREFLY NEUROSCIENCE, For: Jun 25

Fri, 26 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260626/26699318.html

Form 8-K FIREFLY NEUROSCIENCE, For: Jun 25

Fri, 26 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260626/26699318.html

Firefly Neuroscience (AIFF) files for 20.5M share offering by selling stockholders

Tue, 23 Jun 2026 16:07:55 -0400

Firefly Neuroscience (NASDAQ: AIFF) has filed for up to 20,499,999 share offering by selling stockholders.

Firefly Neuroscience (AIFF) files for 20.5M share offering by selling stockholders

Tue, 23 Jun 2026 16:07:55 -0400

Firefly Neuroscience (NASDAQ: AIFF) has filed for up to 20,499,999 share offering by selling stockholders.